Key result
Pharmacological therapies evaluated over the past decade have not successfully reduced the 30-50% incidence of restenosis after angioplasty, prompting new approaches like local drug delivery.
As of 1993, no systemic pharmacological therapy had proven successful in preventing restenosis after angioplasty, prompting a shift toward local delivery and combination therapies.
Answers are grounded in this paper and cite their sources.
Systemic therapies remain unproven for restenosis; leaves open whether local delivery approaches will prove effective in trials.
Restenosis after angioplasty occurs in 30-50% of patients, and a repeat procedure is necessary in 20% within 6 mon. Over the last 10 yr, numerous drugs have been evaluated to reduce this problem. Although none have proven successful, an improved understanding of the pathophysiology, pharmacology, and clinical trial design has resulted. Current approaches to the problem include the use of combination drug therapy, local delivery at site of injury, and use of highly specific drugs including local gene therapy. (Cardiol Rev 1993;1:4, 209-217)
No takes yet. Share an insight, caveat, or question.
David P. Faxon (1993) conducted a review in Restenosis after angioplasty. Pharmacological therapies was evaluated. Pharmacological therapies evaluated over the past decade have not successfully reduced the 30-50% incidence of restenosis after angioplasty, prompting new approaches like local drug delivery.
Synapse has enriched 10 related papers. Consider them for comparative context: